Earnings Call Summary | Select Medical Holdings(SEM.US) Q2 2024 Earnings Conference
Earnings Call Summary | Select Medical Holdings(SEM.US) Q2 2024 Earnings Conference
The following is a summary of the Select Medical Holdings Corporation (SEM) Q2 2024 Earnings Call Transcript:
以下是Select Medical Holdings Corporation (SEM) Q2 2024業績會議呼叫記錄摘要:
Financial Performance:
金融業績:
Select Medical reported a strong Q2 with consolidated adjusted EBITDA growing 3% and revenue growing by 5% compared to Q2 of the prior year.
Outpatient rehab division saw a revenue increase of 4% with patient volumes increasing by the same percentage.
Earnings per share (EPS) were $0.60 for the second quarter compared to $0.61 per share in the same quarter prior year.
Select Medical報告Q2表現強勁,經調整的合併EBITDA增長3%,營業收入相比上一年同期增長5%。
門診康復部門營業收入增長4%,患者數量同比增長相同比例。
第二季度每股收益爲0.60美元,而去年同期爲每股0.61美元。
Business Progress:
業務進展:
Successfully completed Concentra IPO, issuing 22,500,000 shares at a price of $23.50.
Six Select Medical rehabilitation hospitals ranked top nationwide by US News & World Report for 2024-2025.
Opened a new critical illness recovery hospital in Chicago with RUSH University, adding 44 critical illness and 56 rehab beds.
Planning to open additional rehab facilities over 2024-2026 adding 449 beds across various locations.
成功完成Concentra IPO,以23.50美元的價格發行了22,500,000股。
六家Select Medical康復醫院在《美國新聞與世界報道》2024-2025年度全國排名中名列前茅。
與RUSH大學合作,在芝加哥開設了一家新的重症恢復醫院,增加了44個重症和56個康復牀位。
計劃在2024-2026年開設更多康復設施,在各個地點增加449張牀位。
Opportunities:
機會:
Concentra IPO and subsequent developments provide significant financial restructuring and growth opportunities.
Top rankings for rehabilitation hospitals enhance brand prestige and market trust, potentially increasing patient inflow.
Concentra IPO及其後續發展提供了重要的財務重組和增長機會。
康復醫院的高排名加強品牌聲譽和市場信任,有可能增加患者流入。
Risks:
風險:
Startup losses associated with new hospital openings impact immediate profitability.
與新醫院開業相關的創業損失會影響即時的盈利能力。
More details: Select Medical Holdings IR
更多細節:Select Medical Holdings IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。